Status:
COMPLETED
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Lead Sponsor:
Abbott Medical Devices
Conditions:
Angioplasty
Chronic Coronary Occlusion
Eligibility:
All Genders
Brief Summary
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of ...
Eligibility Criteria
Inclusion
- The patient or patient's legally-authorized representative agrees to participate in this study by signing the Ethics Committee-approved informed consent form (ICF).
- Only XIENCE V stent(s) is/are implanted into the coronary vasculature during the index procedure.
Exclusion
- The inability to obtain a signed ICF
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
2605 Patients enrolled
Trial Details
Trial ID
NCT01249027
Start Date
November 1 2010
End Date
January 1 2017
Last Update
March 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abbott Vascular
Santa Clara, California, United States, 95054